The first patient has been dosed in Antengene‘s Phase 1 clinical trial investigating the dual inhibitor ATG-019, alone or in combination with niacin extended release, for people with non-Hodgkin’s lymphoma or advanced solid tumors. ATG-019 is being developed as KPT-9274 by Karyopharm Therapeutics, but Antengene acquired its development and commercialization rights in several Asian countries and regions. The TEACH trial (NCT04281420), taking place in Taiwan, follows the start of a similar Phase 1 trial (NCT02702492) in…
April 21, 2020April 21, 2020